EP Patent

EP3682884C0 — CRYSTALLINE FORMS OF DAPRODUSTAT (GSK1278863), A PERORAL HYPOXIA-INDUCABLE FACTOR PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) FOR THE TREATMENT OF ANEMIA, AND THEIR METHODS OF MANUFACTURING

Assigned to GlaxoSmithKline Intellectual Property No 2 Ltd · Expires 2024-04-24 · 2y expired

What this patent protects

Patent listed against Jesduvroq.

Drugs covered by this patent

Patent Metadata

Patent number
EP3682884C0
Jurisdiction
EP
Classification
—
Expires
2024-04-24
Drug substance claim
No
Drug product claim
No
Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.